crizanlizumab

FDA Drug Profile — ADAKVEO

Drug Details

Generic Name
crizanlizumab
Brand Names
ADAKVEO
Application Number
BLA761128
Sponsor
Novartis Pharmaceuticals Corporation
NDC Codes
1
Dosage Forms
INJECTION
Routes
INTRAVENOUS
Active Ingredients
CRIZANLIZUMAB

Indications and Usage

1 INDICATIONS AND USAGE ADAKVEO ® is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. ADAKVEO is a selectin blocker indicated to reduce the frequency of vasoocclusive crises in adults and pediatric patients aged 16 years and older with sickle cell disease.